YMAB Y-mAbs Therapeutics Inc: רווח למניה לשנה מתגלגלת

The price visualization based on EPS (TTM) for Y-mAbs Therapeutics (YMAB), which assists in the basic asset valuation, is 85.70. Thomas Gad's team focuses on implementing advanced antibodies into pediatric medicine, successfully launching developments onto global markets. The business relies on exceptional pricing power within the pediatric cancer niche due to unique drugs, while growth is based on expanding the therapeutic capabilities of the current product portfolio.
YMAB (ymabs.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Y-mAbs Therapeutics (YMAB) focuses on the independent commercialization of oncology antibodies, minimizing mergers in favor of regional licensing. By analyzing the rolling annual change in EPS, an investor assesses the net profit per share dynamics over the last twelve months. This metric measures the efficiency of development capitalization and the resilience of revenue generation against external shocks. Steady growth confirms the market competitiveness of the drugs, while stagnation signals a risk of business valuation overestimation.